Take a trial of UK to unlock this pageFind out more

Relative Strength (%)
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
Margin of Safety (beta)
Screens Passed 2
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 31st Dec 2009 2010 2011 2012 2013 2014 TTM 2015E 2016E CAGR / Avg
Revenue $m
Operating Profit $m
Net Profit $m
EPS Reported $
EPS Normalised $
EPS Growth %
PE Ratio x
Operating Margin %
Op. Cashflow ps $
Capex ps $
Free Cashflow ps $
Last ex-div: 19th Feb, paid: 23rd Mar more... Dividends
Dividend ps $
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc $m
Working Capital $m
Net Fixed Assets $m
Net Debt $m
Book Value $m
Average Shares m
Book Value ps $ +1.8%

FINANCIAL BRIEF: For the three months ended 31 March 2015, AstraZeneca plc revenues decreased 6% to $6.06B. Net income increased 9% to $550M. Revenues reflect United States segment decrease of 14% to $2.17B, Western Europe segment decrease of 18% to $1.34B. Basic Earnings per Share excluding Extraordinary Items increased from $0.40 to $0.44. more »

Health Trend
Bankruptcy Risk
  Earnings Manipulation Risk
Magic Formula Score
Other Ratios
Leverage (ttm) Total Ex Intang
Gross Gearing %
Net Gearing %
Cash / Assets %
Recent History
Latest interim period (ended 31st Mar '15) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
31st Dec 2015
31st Dec 2016

Price Target: $75.4
(+16.91% above Price)
Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: -1.1% ($) (¢) (¢) ($) (¢) (¢)
Consensus Estimate
1m Change
3m Change
31 brokers Broker Consensus Trend
Broker Recommendations for AstraZeneca
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts: 3 4 14 7 5

Named Brokers and Analysts
Jefferies Jeffrey Holford , Credit Suisse Matthew Weston , SEB Equities Lars Hevreng , Leerink Partners LLC Seamus Fernandez , BERNSTEIN Tim Anderson , Danske Markets Martin Parkhøi Mattias Häggblom Thomas Bowers , Seymour Pierce , Panmure Gordon Savvas Neophytou , Natixis Philippe Lanone Jean-Jacques Le Fur , Mirabaud Securities Nicholas Turner , Swedbank Markets Johan Unnerus , Nordea Markets Erik Hultgaard , Davy , CA Cheuvreux , Societe Generale Justin Smith , Handelsbanken Capital Markets Peter Sehested , Pareto Securities AS Yilmaz Mahshid , Berenberg Alistair Campbell , DZ Bank , Helvea SA Odile Rundquist , Kepler Cheuvreux Sheela Sharma , Charles Stanley Rae Ellingham , Shore Capital Stockbrokers Brian White , Bryan Garnier Eric Le Berrigaud , Morningstar, Inc. Damien Conover , Day by Day Valérie GASTALDY , Landesbank Baden-Wuerttemberg Timo Kuerschner , Liberum Naresh Chouhan , Baader Helvea Equity Research Odile Rundquist ,

Profile Summary

AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. The Company discovers, develops and commercializes prescription medicines for Cardiovascular and Metabolic diseases; Oncology; Respiratory, Inflammation and Autoimmunity, Infection, Neuroscience and Gastrointestinal. The Company's medicines include Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension, heart failure and angina; Onglyza for Type 2; Iressa for lung cancer; Faslodex for breast cancer; Zoladex for prostate and breast cancer; Pulmicort for asthma; Symbicort for asthma and COPD (chronic obstructive pulmonary); Nexium for acid-related diseases; Seroquel XR for schizophrenia, bipolar disorder and depressive disorder, and Synagis for RSV (respiratory syncytial virus), a respiratory infection in infants. The Company's pipeline includes 133 projects, of which 118 are in the clinical phase of development. AstraZeneca operates in over 100 countries.

Directors: Pascal Soriot (CEO) 55, Marc Dunoyer (CFO) 61, Ruud Dobber (EVP) , Caroline Hempstead (EVP) , Paul Hudson (EVP) , Bahija Jallal (EVP) , Mark Mallon (EVP) , Briggs Morrison (EVP) , Menelas Pangalos (EVP) , David Smith (EVP) , Leif Johansson (NEC) 66, Cornelia Bargmann (NED) , Genevieve Berger (NED) 60, Ann Cairns (NED) 57, Marcus Wallenberg (NED) 59,

No. of Employees: 57,500 No. of Shareholders: 100,371

Last Annual December 31st, 2014
Last Interim March 31st, 2015
Shares in Issue 1,263,607,818
Free Float 1.26bn (99.7%)

Address - Legal Department 2 Kingdom Street, LONDON, W2 6BD, United Kingdom
Web http://www.astrazeneca.com/
Phone +44 20 73045000
Contact Karl Hard (IR Contact Officer)
Auditors KPMG LLP

AZN Share Price Performance AZNQuote
-77.5  -1.9%
Traded 4:40pm · Minimum 15 min delayed · NMS: 0.500k

Latest AZN News Announcements (delayed)

Upcoming AZN Events
Friday 24th July, 2015
AstraZeneca PLC Split For AZN
Thursday 30th July, 2015
Q2 2015 AstraZeneca PLC Earnings Release
Thursday 5th November, 2015
Q3 2015 AstraZeneca PLC Earnings Release

Recent ↓
Monday 15th June, 2015
AstraZeneca PLC at Citi European Healthcare Conference
Tuesday 2nd June, 2015
AstraZeneca PLC Analysts and Investors Briefing during the American Society of Clinical Oncology (ASCO) Annual Meeting
Friday 24th April, 2015
AstraZeneca PLC Annual Shareholders Meeting
Friday 24th April, 2015
Q1 2015 AstraZeneca PLC Earnings Call
Friday 24th April, 2015
Q1 2015 AstraZeneca PLC Earnings Release
Wednesday 25th March, 2015
AstraZeneca PLC at Biotechnology Industry Organization (BIO) Asia International Conference
Monday 16th March, 2015
AstraZeneca PLC Investor Science Conference Call ACC 2015
Thursday 19th February, 2015
Dividend For AZN.L
Wednesday 18th February, 2015
Dividend For AZN
Wednesday 18th February, 2015
Dividend For AZN.BA
Thursday 5th February, 2015
Full Year 2014 AstraZeneca PLC Earnings Call
Thursday 5th February, 2015
Full Year 2014 AstraZeneca PLC Earnings Release
Wednesday 14th January, 2015
AstraZeneca PLC at JPMorgan Healthcare Conference
Tuesday 18th November, 2014
AstraZeneca PLC Investor Day
Thursday 6th November, 2014
Q3 2014 AstraZeneca PLC Earnings Call
Thursday 6th November, 2014
Q3 2014 AstraZeneca PLC Earnings Release
Sunday 28th September, 2014
AstraZeneca PLC European Society for Medical Oncology (ESMO) 2014 Analysts and Investors Briefing
Tuesday 23rd September, 2014
AstraZeneca PLC at EBD Group BioPharm America
Wednesday 13th August, 2014
Dividend For AZN.BA
Wednesday 13th August, 2014
Dividend For AZN

Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2015.

Should you buy AZN

Access AZN Analytics Now!

Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis